@dishman Dishman has been awarded manufacture of SIRTURO® (bedaquiline) APT Dishman Pharmaceuticals and Chemicals Limited (Dishman), a leading global manufacturer of pharmaceutical active ingredients, announced today that it holds a license agreement from Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) to produce the a: {bedaquiline), a medicine used in the treatment of Mult TB). manufacturer of API with the USFOA, European Medicines Agency and several other Asian regulatory authorities. Recently, Dishman has started supplying Janssen with the global demand of this API. ‘Tuberculosis (7B) isa major public health concern in india with the World Health Organization estimating there are more than 2.8 million cases of 78.1 articular, the burden of MDR-T@ in inca, is among the most significant in the world with an estimated 64,000 cases’, and for those diagnosed with this deadly disease, fewer than helt are treated successfully", InJanuary 2015, SIRTURO" (bedaquiline) received approval from the Drugs Controller General of india for use in adults (>18 years) as part of combination therapy of pulmonary tuberculosis due to multidrug-resistant Mycobacterium tuberculosis when an effective {treatment regimen cannot otherwise be provided. This approval provides for access to bedaquiline under the Revised National TB Control Program through its Programmatic Management of Drug Resistant TB framework in order to ensure appropriat ishman Pharmaceuticals and Chemicals Limited Reaisered Ofce: Bhodr-R Chambers, Sos Cross Roads, Novengpura,Akmedabed - 380 009 fais Tek +91 (0) 79 26443083 / 26445807 Fax: +91 (0) 79 26420198 - Email: dishman@dishmangroup.com Wab: wirn-dishmangroup.com Government Recognised Export House CIN NO L242306)1 p8apLCo06329@dishman About Multidrug-Resistant Tuberculosis (MOR-TB) MDR-TB i particularly complicated form of TB characterised by resistance to at least two of the standard four-drug, ant-TB drugs." inadequately treated patients are likely to increase selective pressure, allowing resistant bacteria to thrive and pose a significant (ransmission risk to the general population. Without significant public health intervention, MDR-TBis projected to infect more than two million people between 2011 and 2015." Ministry of Health and Family Welfare. 78 indla 2024 Annual Status Report. Available at ited tbcindia nlc in/odts/TB%20INDIA%202014,pcf. Accessed lanuary 2015, | Mlestry of Heath and Family Welfare. TB India 2014~ Annual Status Roper hvstable st itn dontbeindlanicin/pa(TB%2OINDI%202014 pdf. Accessed January 2015, * WHO. Global Tuberculosis Report 2024. Available at ‘Bioufapos who ints /bst-eam/10685 /197094/1/8789241564809 eng pdlPuae1. Accessed January 2015 | WHO. Mutidrug-Resistant Tuberculosis, Online QUA, February 2012, Avelobie ae brtnil/www.who.jnt/Festuces/aa/78/en/lodex hin. Accessed October 2014 |LWHO. Partners call for increased commitment to tackle MOR-TB. 23 March 2013, Available at ‘tipi wn. who,Int/mediacentre/news/releases/2011/TBdey 2110322/en/in Accessed October 2014 Dishman Pharmaceuticals and Chemicals Limited Registered Office: Bhadr-Roj Chombers, Swostk Cross Roads, Nowrangpuro, Ahmedabad ~ 380 009 india Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198 NN Email: dshmen@dishmangroup.com Webs wiw.dishmangroup.com Government Recognised Export House IN NO 1242306) 983°1C006329